Inovio Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Inovio Pharmaceuticals generated cash of -$124,365,551, which is more than the previous year. Cash used in financing activities reached the amount of $4,995,099 last year. Net change in cash is therefore -$32,018,497.
Cash Flow
| 2014 | -29.82M | -35.81M | 72.46M |
|---|---|---|---|
| 2015 | -12.43M | -54.82M | 84.35M |
| 2016 | -62.55M | 16.27M | 7.78M |
| 2017 | -63.20M | -27.83M | 95.69M |
| 2018 | -73.55M | 42.41M | 31.03M |
| 2019 | -97.85M | -9.04M | 105.39M |
| 2020 | -177.97M | -58.79M | 465.27M |
| 2021 | -215.70M | -175.34M | 211.49M |
| 2022 | -216.21M | 109.58M | 81.84M |
| 2023 | -124.36M | 87.35M | 4.99M |
INO Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 46.32M | 71.14M | 250.72M | 22.19M | 23.69M | 23.78M | 19.13M | 57.63M | 40.54M | 33.71M |
Operating activities | ||||||||||
Net income | -135.11M | -279.81M | -303.65M | -167.47M | -120.55M | -96.96M | -88.20M | -73.74M | -29.10M | -36.14M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 3.50M | 5.49M | 4.73M | 4.62M | 5.51M | 4.99M | 3.46M | 3.08M | 1.91M | 1.56M |
Stock-based compensation expense | 11.07M | 22.55M | 26.33M | 15.64M | 10.90M | 0 | 13.07M | 10.47M | 6.18M | 5.42M |
| Deferred income tax benefit | 11.07M | 22.55M | 26.33M | 15.64M | 10.90M | 0 | 13.07M | 10.47M | 6.18M | 5.42M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 9.33M | -3.70M | 11.03M | -17.01M | 2.02M | 2.43M | 10.08M | -9.23M | -4.52M | 497.35K |
Inventories | 0 | 0 | 15.54M | -55.15M | 935.79K | -963.92K | 531.86K | 592.01K | 1.04M | 441.94K |
Accounts payable | -45.98M | 32.60M | 26.14M | 3.25M | -4.58M | 601.25K | 2.68M | 7.27M | 6.59M | 993.22K |
Cash generated by operating activities | -124.36M | -216.21M | -215.70M | -177.97M | -97.85M | -73.55M | -63.20M | -62.55M | -12.43M | -29.82M |
Investing activities | ||||||||||
Purchases Of Investments | -203.47M | -248.52M | -348.95M | -156.21M | -100.95M | -88.15M | -95.70M | -57.31M | -63.52M | -47.18M |
Investments In Property Plant And Equipment | -320.89K | -969.15K | -1.23M | -1.52M | -987.92K | -2.08M | -10.29M | -3.93M | -2.78M | -1.37M |
Acquisitions Net | 0 | -1.99M | 1.43T | 38.72M | 987.92B | 2.77T | 0 | -1.2M | 0 | 1.37M |
Cash generated by investing activities | 87.35M | 109.58M | -175.34M | -58.79M | -9.04M | 42.41M | -27.83M | 16.27M | -54.82M | -35.81M |
Financing activities | ||||||||||
Common Stock Issued | 5.46M | 82.95M | 209.44M | 454.48M | 9.08M | 29.22M | 94.34M | 0 | 81.90M | 59.20M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | -4.61M | -4.02M | 0 | -611.61K | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | -171.62K | 97.44M | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 4.99M | 81.84M | 211.49M | 465.27M | 105.39M | 31.03M | 95.69M | 7.78M | 84.35M | 72.46M |
Net Change In Cash | -32.01M | -24.81M | -179.58M | 228.53M | -1.49M | -92.94K | 4.65M | -38.49M | 17.08M | 6.82M |
Cash at end of period | 14.31M | 46.32M | 71.14M | 250.72M | 22.19M | 23.69M | 23.78M | 19.13M | 57.63M | 40.54M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |